BiotechTube

Satralizumab (Genetical Recombination)

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Arterial Hypertension

Conditions

Pulmonary Arterial Hypertension

Trial Timeline

Jul 12, 2022 → Jun 30, 2026

NCT ID
NCT05679570

About Satralizumab (Genetical Recombination)

Satralizumab (Genetical Recombination) is a phase 2 stage product being developed by Chugai Pharmaceutical for Pulmonary Arterial Hypertension. The current trial status is active. This product is registered under clinical trial identifier NCT05679570. Target conditions include Pulmonary Arterial Hypertension.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05679570Phase 2Active

Competing Products

20 competing products in Pulmonary Arterial Hypertension

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
44
macitentan 10 mgBML, Inc.Phase 3
76
tadalafil + tadalafilEli LillyPhase 3
77
CS1 AdministrationCereno ScientificPhase 2
47
CS1Cereno ScientificPre-clinical
18
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
41
DS-9231 + PlaceboDaiichi SankyoPhase 2
52
RegadenosonAstellas PharmaPre-clinical
23
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
MonteplaseEisaiApproved
85
lysozyme 90 mg + PlaceboEisaiApproved
85
Prednisolone + VoriconazoleCiplaPhase 2/3
65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
52
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
85
Tadalafil- Tablet or Oral suspensionEli LillyPhase 1/2
41

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77